dismiss

Clean Sweep Live Auction on Thur. March 28th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Endroit courant :
>
> This Story


Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment
Advertisement

 

advertisement

 

Molecular Imaging Homepage

RadioMedix and Vect-Horus to develop brain theranostic agent for brain cancer Provide diagnosis and treatment of Glioblastoma Multiforme (GBM)

NIH awards $1.8 million to Magnetic Insight for neurovascular MPI Detects magnetic nanoparticle tracers, enables deep-tissue imaging

DOE to cut Moly-99 deals with four US firms Could be as much as $15 million per company, with partners matching awarded amounts

Women's brains appear three years younger than men's at the same age: PET study A machine-learning algorithm assisted with the analysis

Dennis Durmis MITA names chair of board of directors

Researchers find new PET tracer that better detects melanoma than 18F-FDG 18F-P3BZA could become the new gold standard

RadioMedix scores $2 million contract for Targeted Alpha-emitter therapy Treatment for neuroendocrine tumors

FDA clears United Imaging's total-body PET scanner Creating 3D images of entire human body in 15-30 seconds

FDA clears MIM SurePlan molecular radiotherapy software Can measure the absorbed dose from MRT for individual patients

Rob Beanlands ASNC names president for 2019

Denos Health Management
launches Zionexa

Following Cyclopharma sale, Denos launches radiopharmaceutical company, Zionexa

par John R. Fischer , Staff Reporter
Denos Health Management, the former primary stakeholder of PET diagnostics manufacturer Cyclopharma France and U.S., is starting from scratch in the radiopharmaceutical industry following its sale of the French-based enterprise, with the launch of Zionexa.

Formerly the U.S. division of Cyclopharma, the new company will focus on clinically developing and commercializing innovative companion diagnostic and therapeutic radiopharmaceuticals to enhance patient care. Its establishment follows the recent acquisition of Cyclopharma by Curium.

Story Continues Below Advertisement

Has exclusive distribution agreement with DDD to sell new Camera systems

UMRi provides the very best new & refurbished gamma cameras, quality parts &repair services. We also rebuild & replace camera detectors, move camera systems across town or across the country. Call us at 888-239-3510



“It was the right time,” Peter Webner, Zionexa CEO and former CEO of Cyclopharma U.S., told HCB News. “They were looking to get their equity out. Curium was looking at growing its footprint and a decision was made at the board level for Cyclopharma that they wanted to focus on the new products coming down the pipe.”

Announced in April and completed in May, the deal provided Curium access to nearly 100 employees and seven PET radiopharmacies throughout France, enabling it "comprehensive coverage of all 140 PET centers across France,” as stated in its announcement of the transaction.

Existing R&D and international operations of Cyclopharama though were not included in the agreement.

In addition to acquiring Cyclopharma’s U.S. division, Denos Health Management purchased the rights to the pipeline of Cyclopharma France, including EstroTep, a PET tracer cleared for use only in France.

Denos Health Management also adds value from early pharmacodynamics studies (Phase 0), early human kinetics and dosimetry and proof of concept imaging (Phase 1), target development and process and chemistry improvement (Phase 2), pivotal clearance trials (Phase 3), commercialization and distribution, and market access strategy.

Zionexa plans to gain FDA clearance for EstroTep and is currently working on clinical trials for several other products including IMAKinib, designed to target the EGFR protein in lung cancer.

A third product is also in the works. Webner could not comment on it at this time but did say that all three are fluorine-based and would “fit naturally into the mix of commercial and academic cyclotron capabilities in the U.S.”

EstroTep is planned as the first of the three to be submitted to the FDA for market clearance.

Submissions are set to begin this summer.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Publicité
Développez la notoriété de votre marque
Enchères + Ventes Privées
Obtenir le meilleur prix
Acheter des équipement / pièces
Trouver le meilleur prix
Infos du jour
Lire Les dernières nouvelles
Annuaire
Consulter tous les utilisateurs DOTmed
Éthique concernant DOTmed
Voir notre programme d'éthique
L'or partie le programme de fournisseur
Recevoir des demandes PH
Programme de marchand de service d'or
Recevoir des demandes
Fournisseurs de soins de santé
Voir tous les outils des HCP (abréviation pour les professionnels de la santé)
Les travaux/Formation
Trouver / combler un poste
Parts Hunter +EasyPay
Obtenir des devis de pièces
Certification Récentes
Voir les utilisateurs récemment certifiés
Evaluation Récentes
Voir les utilisateurs récemment certifiés
Central de location
Louer de l’équipement à moindre prix
Vendre des équipements / pièces
Obtenir le maximum d'argent
Service le forum de techniciens
Trouver de l'aide et des conseils
Simple demande de propositions
Obtenir des devis pour des appareils
Expo Virtuelle
Trouver des services d'appareils
L'Access et l'utilisation de cet emplacement est sujet aux modalités et aux conditions du notre de nos MENTIONS LEGALES & DONNEES PERSONELLES
Propriété de et classe des propriétaires DOTmedà .com, inc. Copyright ©2001-2019 DOTmed.com, Inc.
TOUS DROITS RÉSERVÉS